Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun Gets U.S. FDA Clearance For Lilly Cancer Generic

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA cleared Sun Pharmaceutical Industries to market its generic drug for treating cancer in combination with other drugs. The cleared drug is Sun's version of Lilly's Gemzar (gemcitabine) injectable. Gemzar has produced annual sales of about $680 million for Lilly in the United States alone. The drug is combined with other anti-cancer drugs to treat the disease. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts